Idiopathic pulmonary fibrosis medical therapy

Jump to navigation Jump to search

Idiopathic pulmonary fibrosis Microchapters


Patient Information


Historical Perspective




Differentiating Idiopathic pulmonary fibrosis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray



Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Idiopathic pulmonary fibrosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Idiopathic pulmonary fibrosis medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Idiopathic pulmonary fibrosis medical therapy

CDC on Idiopathic pulmonary fibrosis medical therapy

Idiopathic pulmonary fibrosis medical therapy in the news

Blogs on Idiopathic pulmonary fibrosis medical therapy

Directions to Hospitals Treating Idiopathic pulmonary fibrosis

Risk calculators and risk factors for Idiopathic pulmonary fibrosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]


The mainstay of therapy for idiopathic pulmonary fibrosis is the supportive care measures which include mechanical ventilation, pulmonary rehbilitation, and vaccination against influenza and pneumococcus. Medical treatment as nintedanib and pirfenidone can be administrated to slow the disease progression.

Medical Therapy

Supportive care

  • Patients with idiopathic pulmonary fibrosis receive supportive care alongside the medical therapy.[1]
  • Supportive care measures include the following:
    • Mechanical ventilation: Nearly all the patients with IPF require oxygen supplementation.
    • Pulmonary rehabilitation
    • Vaccination against possible causes of pulmonary inflammation as influenza and pneumococcal polysacchride capsule vaccines.[2]

Medical treatment

  • There is no specific treatment for idiopathic pulmonary fibrosis. However, there are two medications, nintedanib and pirfenidone, that can be administrated in order to slow the disease progression.[3]
  • Medical treatment may include the following therapies:
    • Preferred regimen (1) : Nintedanib 150 mg PO q12h 
    • Preferred regimen (2):
      • Day 1 to 3: Pirfenidone 267 mg PO q8h 
      • Days 8 to 14: Pirfenidone 534 mg PO q8h 
      • Follwoing days: Pirfenidone 801 mg PO q8h


  1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK; et al. (2011). "An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management". Am J Respir Crit Care Med. 183 (6): 788–824. doi:10.1164/rccm.2009-040GL. PMC 5450933. PMID 21471066. Review in: Ann Intern Med. 2011 Jun 21;154(12):JC6-8
  2. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG; et al. (2014). "Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Morb Mortal Wkly Rep. 63 (37): 822–5. PMC 5779453. PMID 25233284.
  3. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J; et al. (2015). "An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline". Am J Respir Crit Care Med. 192 (2): e3–19. doi:10.1164/rccm.201506-1063ST. PMID 26177183.

Template:WH Template:WS [[Category:Primary Care]